摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲基-1H-四唑-5-硫醇钾 | 62557-28-2

中文名称
1-甲基-1H-四唑-5-硫醇钾
中文别名
——
英文名称
potassium 5-mercapto-1-methyltetrazole
英文别名
1-methyl-5-mercapto-1,2,3,4-tetrazole potassium salt;(1-methyltetrazol-5-yl)sulfanyl potassium;potassium 1-methyl-1H-tetrazole-5-thiolate;potassium;1-methyltetrazole-5-thiolate
1-甲基-1H-四唑-5-硫醇钾化学式
CAS
62557-28-2
化学式
C2H3N4S*K
mdl
——
分子量
154.237
InChiKey
HFRHYYFCSVBNPW-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.88
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    44.6
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    1-甲基-1H-四唑-5-硫醇钾 作用下, 以 甲醇 为溶剂, 以70%的产率得到5,5-二硫代双(1-甲基四唑)
    参考文献:
    名称:
    COMPOUND HAVING HEPTAMETHINE STRUCTURE, SENSITIZING DYE AND PHOTOELECTRIC CONVERSION ELEMENT
    摘要:
    提供的是一种具有七甲基结构的化合物,其通式如下(1),用作光电转换装置的敏化染料,以及使用该化合物作为敏化染料的光电转换装置,可以解决相关技术中的问题。在通式(1)中,R1和R2分别代表氢原子、烷基或芳基;R3至R6每个代表具有1到18个碳原子的烷基;X代表卤素原子;Y代表一价阴离子;当R3至R6每个具有1到5个碳原子时,Z代表烷基、烷氧基或芳基;当R3至R6每个具有6到18个碳原子时,Z代表氢原子、烷基、烷氧基或芳基;m和n各代表1到12的整数。
    公开号:
    EP2684872A1
  • 作为产物:
    描述:
    1-甲基-5-巯基-1H-四氮唑potassium carbonate 作用下, 以 甲醇 为溶剂, 以82%的产率得到1-甲基-1H-四唑-5-硫醇钾
    参考文献:
    名称:
    COMPOUND HAVING HEPTAMETHINE STRUCTURE, SENSITIZING DYE AND PHOTOELECTRIC CONVERSION ELEMENT
    摘要:
    提供的是一种具有七甲基结构的化合物,其通式如下(1),用作光电转换装置的敏化染料,以及使用该化合物作为敏化染料的光电转换装置,可以解决相关技术中的问题。在通式(1)中,R1和R2分别代表氢原子、烷基或芳基;R3至R6每个代表具有1到18个碳原子的烷基;X代表卤素原子;Y代表一价阴离子;当R3至R6每个具有1到5个碳原子时,Z代表烷基、烷氧基或芳基;当R3至R6每个具有6到18个碳原子时,Z代表氢原子、烷基、烷氧基或芳基;m和n各代表1到12的整数。
    公开号:
    EP2684872A1
点击查看最新优质反应信息

文献信息

  • 3-Substituted-7-substituted alkanamido-3-cephem-4-carboxylic acid
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04254260A1
    公开(公告)日:1981-03-03
    3-Substituted-7-substituted alkanamido-3-cephem-4-carboxylic acid compounds and pharmaceutically acceptable salts thereof which have antimicrobial activities, processes for the preparation thereof, pharmaceutical compositions comprising the same, and methods of using the same therapeutically in the treatment of infections.
    3-取代-7-取代烷基基-3-头孢烯-4-羧酸化合物及其具有抗微生物活性的药用盐,其制备方法,包括相同化合物的药物组合物,以及在治疗感染方面的治疗使用方法。
  • Inhibition of human leukocyte elastase. 3. Synthesis and activity of 3'-substituted cephalosporins
    作者:Shrenik K. Shah、Karen A. Brause、Gilbert O. Chandler、Paul E. Finke、Bonnie M. Ashe、Hazel Weston、Wilson B. Knight、Alan L. Maycock、James B. Doherty
    DOI:10.1021/jm00171a030
    日期:1990.9
    Several 3'-substituted cephalosporin sulfones were synthesized from 3-(hydroxymethyl)cephalosporin, which was prepared by Ti(OiPr)4 hydrolysis of the corresponding acetate. A method was also developed to prepare a 3-vinylcephalosporin. Some of these compound were found to be potent time-dependent inhibitors of human leukocyte elastase (HLE). The HLE inhibitory activity was correlated with sigma 1 and it was concluded that the potency was determined by the electron-withdrawing ability as well as the size of the substituent. A mechanism for inhibition of HLE by cephalosporin sulfones is proposed.
  • SHAH, SHRENIK K.;BRAUSE, KAREN A.;CHANDLER, GILBERT O.;FINKE, PAUL E.;ASH+, J. MED. CHEM., 33,(1990) C. 2529-2535
    作者:SHAH, SHRENIK K.、BRAUSE, KAREN A.、CHANDLER, GILBERT O.、FINKE, PAUL E.、ASH+
    DOI:——
    日期:——
  • [EN] NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS THIOPHÉNOLIQUES À SUBSTITUTION SPÉCIFIQUE
    申请人:[en]NERVIANO MEDICAL SCIENCES S.R.L.
    公开号:WO2024028169A1
    公开(公告)日:2024-02-08
    The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory activity against Werner helicase protein (WRN, RECQL2) and are thus useful in the therapy or treatment of cancer. Furthermore, the invention relates to the use of the compounds according to the invention to inhibit the activity of one or more helicases, preferably including Werner Helicase (WRN) and pharmaceutical composition comprising such compounds. Formula (I).
查看更多